Patent: 9,920,311
✉ Email this page to a colleague
Summary for Patent: 9,920,311
| Title: | PEGylated L-asparaginase |
| Abstract: | Disclosed is a conjugate of a protein having substantial L-asparagine aminohydrolase activity and polyethylene glycol. In particular, the polyethylene glycol has a molecular weight less than or equal to about 5000 Da and the protein is an L-asparaginase from Erwinia. The conjugate of the invention has shown superior properties such as maintenance of a high level of in vitro activity and an unexpected increase in half-life in vivo. Also disclosed are methods of producing the conjugate and use of the conjugate in therapy. In particular, a method is disclosed for use of the conjugate in the treatment of cancer, particularly Acute Lymphoblastic Leukemia (ALL). More specifically, a method is disclosed for use of the conjugate as a second line therapy for patients who have developed hypersensitivity or have had a disease relapse after treatment with other L-asparaginase preparations. |
| Inventor(s): | Abribat; Thierry (Sainte Foy les Lyon, FR) |
| Assignee: | Jazz Pharmaceuticals II SAS (Lyons, FR) |
| Application Number: | 14/819,305 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,920,311
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2030-03-30 |
| Jazz Pharmaceuticals, Inc. | ERWINAZE | asparaginase erwinia chrysanthemi | For Injection | 125359 | 11/18/2011 | ⤷ Try a Trial | 2030-03-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
